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Abstract—Monoacylated derivatives of a complete set of 2,3- and 3,4-vicinal diols of steroids were prepared by regioselective lipase-
catalysed transesterification reactions. The enzymes displayed different selectivities towards the vicinal diols depending on the configuration
of the hydroxyl groups.
q 2005 Elsevier Ltd. All rights reserved.1. Introduction
Polyhydroxylated steroids bearing vicinal diols on the
A-ring are frequently found in Nature and some of them
have relevant biological activities. For instance, the trans-
diaxial 2b,3a-di-hydroxy pattern is present in natural
sulphated sterols with antiviral1 or anti-angiogenic2 action,
while 2a,3a-diols isolated from marine sources hold
cytotoxic activity.3 Steroidal saponins displaying trans-
diequatorial 2a,3b-vicinal diols are quite frequent as
gitogenin derivatives with antitumor properties.4 In turn,
the 3b,4b-diol functionality is present in a variety of steroids
like in the agosterols, which induce reversal of multidrug
resistance5 and proteasome inhibition,6 as well as in
formestane metabolites7 and in volkendousins, which are
potent antitumor agents.8 Finally, the 3a,4b-vicinal diol
pattern has been identified in contignasterol, a natural anti-
inflammatory compound9 and, recently, in a steroid
possessing chemotaxis activity.10
The discovery that lipases and proteases are able to act in
organic solvents opened the way to an intensive synthetic
exploitation of these biocatalysts, which, as shown in
hundreds of papers and several industrial applications,
display remarkable chemo-, regio- and stereoselectivity.11
Specifically in the steroids field, enzyme catalysis can play
an important role for the mild and selective interconversion
of functional groups via regioselective transformations.12–190040–4020/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
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e-mail: samelo@ci.uc.ptStudies on the transesterification of polyfunctionalyzed
steroids have shown that hydrolases can have access to
substituents either on the A-ring or on the D-ring and/or on
the side-chain of steroids. Several lipases showed a
preference for C-3 hydroxyl groups,13,14 whereas the
protease subtilisin Carlsberg catalysed the acylation of
C-17 OH.14 Moreover, stereoselective resolutions of
epimeric alcohols located on the steroid side-chain have
been carried out by lipase PS15 and, more recently, by
subtilisin.16
Concerning the modifications of A-ring substituents, the
selectivity of lipases for 3-hydroxysteroids has been applied
to the chemoenzymatic synthesis of pharmacologically
relevant tibolone metabolites.17 Quite recently, we have
reported a highly selective lipase-catalysed preparation of
epimerically pure 5a,6a- and 5b,6b-epoxysteroids through
acylation or deacylation reactions at the C-3 OH.18 Finally,
the ability to discriminate among different hydroxyl groups
on the A-ring has been demonstrated in the esterification of
ecdysteroids catalysed by Candida antarctica lipase, which
afforded the 2b-monoacyl derivatives in good yields.19
In this context, to further explore the enzymatic transform-
ations of steroids, we endeavoured a systematic study on the
selectivity of commercially available lipases towards a
complete set of stereoisomeric 2,3- and 3,4-vicinal diols, to
provide a new tool for the selective transformation of these
molecules and of related natural compounds.2. Results and discussion
Different synthetic strategies were used to afford theTetrahedron 61 (2005) 3065–3073
Table 1. Lipase-catalysed monoacylation of vicinal diolsa
Substrate Novozym
435
C. rugosa
lipase
Lipase
AY
Lipase
PS
Lipase
AK
C. viscosum
lipase
Porcine pancreatic
lipase
Lipozyme
IM 20
Lipase
CE
1 K CC C C C C K K K
2 K C C CC C C K K K
3 CC K K K K K K K K
4 CC Cb Cb CC K K K K K
5 C CC CC C C C K K K
6 C C C C C CC K K K
7 K C K CC C C K K K
8 K K K K K K K K
a Conversion and product(s) formation was evaluated by TLC.
b The formation of two products was observed.
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dihydroxylation method, which is known to be selective for
the more hindered b-face of 5a-steroids,20 was applied to
D2- or D3-unsaturated precursors affording the cis-b diols
1 and 5 (Scheme 2). Complementarily, the cis-a diols 3 and
7 were accessed through osmium tetroxide-mediated
dihydroxylation on the same olefins.21 Trans-diequatorial
diols 2 and 6 were obtained by two different approaches.
Starting from cholestan-3-one, a-acetoxylation by lead
tetracetate,22 followed by stereoselective reduction by
NaBH4/CeCl3 and deacetylation rendered the diol 2. On
the other hand, the 3b,4a-diol 6 was directly accessed by
hydroboration of the D4-3-one precursor.23 Finally, trans-
diaxial diols 4 and 8 were obtained by epoxide opening
reactions.
As shown in the formula, the 2,3-diols were prepared
by modifying the cholestane skeleton, whereas the diffi-
culties found on separating the 5a- and 5b-epimers of
D3-cholestane by sequential crystallizations led us to
prepare the set of 3,4-diols in the androstane series. The
cholestane derivative 9 was also synthesised to confirm that
lipases selectivity towards the A-ring OH was not affected
by different substituents on the D-ring.
The performances of a panel of 9 commercial lipases were
evaluated for the esterification of the vicinal diols 1–9, using
vinyl acetate as the acyl donor and toluene or acetone/THF
as solvents for the cholestane or the androstane derivatives,
respectively. TLC monitoring allowed the identification,
for each substrate, of the lipase(s) able to promote the
monoacylation of the substrates. As shown in Table 1, all
the stereoisomeric vicinal diols were accepted as substrates
by some of the enzymes tested with the exception of
compound 8.
Lipases from different sources (Candida antarctica, column
2; Candida rugosa, columns 3 and 4; Pseudomonas strains,
columns 5 and 6; Chromobacterium viscosum, column 7)
were able to acylate the target compounds. Usually more
than one enzyme was acting on the same substrate, with theScheme 1.notable exception of compound 3 (2a,3a-diol) acylated only
by Novozym 435 (immobilized lipase B from Candida
antarctica). Enzymatic acylations were highly regioselec-
tive, showing the formation of only one product by TLC,
with the exception of Candida rugosa lipase (from Sigma or
Amano) acting on compound 4. Noteworthy, lipase PS and
Novozym 435 showed complementary regioselectivity
towards compound 4.
For each substrate the best performing lipase (evaluated by
TLC) was chosen for scale-up reactions, allowing the
isolation of the corresponding monoester in good yields
(Scheme 1). Products identification was easily done by
NMR analysis (downfield shift of the signals due to the
proton geminal to the acylated OH) and, when possible, by
comparison with literature data.
The general preference of lipases for the C-3 OH13,14 was
observed with most of the substrates (Scheme 2). Specifi-
cally, the diequatorial vicinal diols 2 and 6 were converted
into the corresponding 3b-acetate, showing a common
preference of different lipases toward a 3b-equatorial OH
in the presence of 2a-equatorial OH (substrate 2) or of
4a-equatorial OH (substrate 6).
Concerning the diaxial 2b,3a- and 3a,4b-diols (substrates 4
and 8), different outcomes were noticed. The diaxial 2b,3a-
diol was differently accepted by the lipases tested. Whereas
Novozym 435 converted this diol exclusively into the
3a-acetate 4a, lipase PS showed opposite selectivity
rendering the 2b-acyl derivative 4b as the only product.
Moreover, acylations catalysed by Candida rugosa lipases
were not regioselective with this substrate. Conversely, the
diaxial 3a,4b diol (8) was not accepted by any of the
enzymes tested.
Finally, the equatorial/axial 2a,3a-diol (3), only accepted
by Novozym 435, was acylated at the axial 3a-position,
while, at variance, the 3a,4a-dihydroxy steroid (7) display-
ing axial/equatorial configuration, was acylated by different
lipases at its equatorial 4a-OH.
Scheme 2.
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lipases tested did not catalyse any acylation of the 17b-OH
(substrates 5–8), that was found unaffected in each of the
isolated products.
The ability of Novozym 435 to accept axial 3a-OH as a
nucleophile has been reported previously.13d Herein, we
noticed that this lipase catalyses the acylation of the 3a-OH
even when a second hydroxyl is located at C-2 (substrates 3
and 4), whereas the enzyme is inactive when the other OH is
located at C-4 (substrates 7 and 8).
Concerning lipase PS, the ability of this enzyme to esterify
3-hydroxy steroids has been previously observed with
3b-hydroxy-5,6-epoxy derivatives.18 In the present work,
lipase PS was found able to acylate most of the substrates
(Table 1), catalysing their regioselective modification, not
only at equatorial C-3 (product 2a), but also at equatorial C-4
(product 7a) and axial C-2 (product 4a). Noteworthy, among
the panel of tested enzymes, lipase PS was the only one able
to acylate hydroxy groups located at the latter positions.
Candida rugosa lipase accepted most of the substrates.Specifically, this enzyme catalysed the acetylation of
substrates 1, 2, 5 and 6 at their 3b-OH, as was expectable
from previous studies.13b,c However, the 3a,4a-diol 7 was
also acylated by Candida rugosa lipase at the C-4 OH, and
the 2b,3a-diol 4 was acylated at both its hydroxy groups,
showing that this enzyme has a quite variable affinity and
selectivity pattern.
Chromobacterium viscosum lipase, which is known to have
a strict selectivity for the 3b-hydroxyl of 5a-steroids,14
showed the expected preference for diols carrying this OH
(substrates 1, 2, 5 and 6). In addition, acylation of the
substrate 7 was also noticed, but at the 4a-OH.
Finally, the substrate 9, a cholestane displaying 3b,4a-
diequatorial configuration, was converted into the 3b-mono-
acetate 9a, a result which confirmed that the differences in the
steroid side chain do not influence the selectivity of lipases.3. Conclusions
The reported results clearly show that lipases are able to
M. M. Cruz Silva et al. / Tetrahedron 61 (2005) 3065–30733068discriminate vicinal hydroxy groups located on the A-ring
of steroids, being sensitive to the configuration of the
different diols and affording the monoesters with high
regioselectivity and good yields.
Considering the occurrence of steroidal vicinal diols in
Nature, some of which being mono-acylated,3,6 -glycosyl-
ated4 or -sulphated,1,10 these findings can offer useful
synthetic tools for the preparation of these compounds and
of related derivatives.4. Experimental
4.1. General
All commercially available chemicals were used as supplied
by the manufacturers. Steroids, porcine pancreatic lipase
(13.3 U/mg) and crude Candida rugosa lipase (665 U/mg)
were from Sigma. Novozym 435 (8600 PLU/g) and
Lipozyme IM 20 (24 BIU/g) were from Novozymes. Lipase
PS (30.8 U/mg, from Pseudomonas cepacia) was purchased
from Amano and adsorbed on celite as described else-
where.16 Lipases AK (20 U/mg, from Pseudomonas
fluorescens), CE (5.5 U/mg, from Humicola lanuginosa)
and AY (30 U/mg, from Candida rugosa) were from
Amano. Chromobacterium viscosum lipase (100 U/mg)
was supplied by Finnsugar. 1H and 13C NMR spectra were
recorded on a Bruker AC-300 at 300 M Hz and at
75.47 M Hz, respectively, using CDCl3 and CD3OD as
solvents. Chemical shifts are reported on the d (ppm) scale
and are relative to tetramethylsilane as internal standard.
Infrared spectra were recorder on a Jasco FT/IR-420
spectrometer. Mass spectra were recorded on a GCT
Micromass spectrometer. Melting points were measured in
a Bu¨chi B-540. Flash chromatography was performed using
silica gel (230–400 Mesh) from Merck and petroleum ether/
ethyl acetate mixtures as eluents. TLC monitoring was done
in petroleum ether/ethyl acetate as eluent and detected with
the Komarowsky’s reagent.24
4.2. Chemical synthesis of the diols
4.2.1. Cholestane-2b,3b-diol (1). According to a known
procedure,25 silica gel (70–230 Mesh, 100 g) was added to a
solution of p-toluenesulfonic acid (3 g) in acetone (20 ml).
The mixture was stirred, then evaporated under reduced
pressure and left in a vacuum oven for 2 days. A mixture of
cholestan-3b-ol (1.17 g, 3 mmol), p-toluenesulfonic acid/
silica (15 g) and anhydrous toluene (200 ml) was stirred
under reflux, until the consumption of the starting material
(24 h). After cooling, diethyl ether was added and the silica
was removed by filtration. The organic solution was washed
with water, saturated bicarbonate solution and brine. Upon
evaporation, cholest-2-ene (1.0 g, 90%) was recovered as a
single product.
Selected data: 1H NMR (CDCl3) d: 0.66 (3H, s, CH3-18),
0.75 (3H, s, CH3-19), 0.86 (6H, two d, JZ6.6 Hz, CH3-26
and CH3-27), 0.90 (3H, d, JZ6.5 Hz, CH3-21), 5.59 (2H, m,
H-2 and H-3). 13C NMR d: 125.96, 125.85, 56.49, 56.27,
54.07, 42.47, 41.45, 40.03, 39.78, 39.51, 36.17, 35.79,35.61, 34.69, 31.82, 30.31, 28.77, 28.22, 28.00, 24.20,
23.82, 22.82, 22.56, 20.90, 18.68, 11.98, 11.67.
To a solution of cholest-2-ene (420 mg, 1.15 mmol) in
glacial acetic acid (35 ml), I2 (600 mg) and Cu(OAc)2
(500 mg) were added and the reaction mixture was refluxed
under magnetic stirring. After 6 h the reaction was complete
(TLC control). Then, toluene and NaCl were added and the
insoluble salts were filtered off. Diethyl ether was added to
the filtrate and the organic phase was washed with water and
saturated sodium bicarbonate solution. Evaporation of the
solvents under reduced pressure rendered the crude product,
which was dissolved in ethanol/chloroform (4:1) (20 ml),
and treated with NaOH 16% aqueous solution (1 ml) for 2 h.
Finally, upon addition of chloroform, the organic layers
were washed with water, HCl 5%, and brine and evaporated
to dryness. The residue was purified by flash chroma-
tography (petroleum ether/ethyl acetate 4:1), affording pure
cholestane-2b,3b-diol (1, 270 mg, 58%), which was crystal-
lized from n-hexane, mp 173–175 8C (lit. 174–17721a and
175–17626 8C).
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.86 (6H, two d, JZ6.6 Hz, CH3-26 and CH3-27), 0.89 (3H,
d, JZ6.5 Hz, CH3-21), 1.00 (3H, s, CH3-19), 3.63 (1H, dt,
JZ4.6, 10.8 Hz, H-3a), 4.02 (1H, brq, H-2a). 13C NMR d:
72.42, 70.22, 56.41, 56.26, 55.24, 45.33, 43.17, 42.62,
40.03, 39.50, 36.16, 35.78, 35.23, 34.83, 32.54, 31.96,
28.34, 28.22, 27.99, 24.17, 23.81, 22.80, 22.55, 21.29,
18.64, 14.56, 12.09. FTIR (ATR): nmax 1049.1, 2850.3–
2931.3, 3311.2 cmK1.
4.2.2. Cholestane-2a,3b-diol (2). Glacial acetic acid
(60 ml) was refluxed with acetic anhydride (5 ml) for
10 min, then cholestan-3-one (769 mg, 2 mmol) was added
and, finally, lead tetracetate (1.5 g, 3.4 mmol) was slowly
added. The reaction was heated under reflux, with magnetic
stirring until the consumption of the starting material (24 h).
After cooling, diethyl ether was added and the organic
solution was washed with HCl 5%, saturated bicarbonate
solution and brine. The crude product was purified by
flash chromatography (petroleum ether/ethyl acetate 5:1)
affording pure 3-oxocholestan-2a-yl acetate (710 mg, 80%),
as a white amorphous powder, mp 120–122 8C (lit.27 124.7–
125.2 8C).
Selected data: 1H NMR (CDCl3) d: 0.67 (3H, s, CH3-18),
0.85 0.91 (9H, CH3-21, CH3-26 and CH3-27), 1.12 (3H, s,
CH3-19), 2.15 (3H, s, CH3CO), 5.29 (1H, dd, JZ6.6,
12.9 Hz, H-2b). 13C NMR d: 204.3, 170.15, 74.46, 56.16,
56.06, 53.78, 47.84, 44.82, 43.57, 42.56, 39.71, 39.47,
37.18, 36.10, 35.74, 34.67, 31.56, 28.38, 28.20, 27.99,
24.16, 23.78, 22.80, 22.54, 21.60, 20.79, 18.63, 12.75,
12.04. FTIR (ATR): nmax 1222.7, 1727.9, 1750.1 cm
K1.
To a solution of 3-oxocholestan-2a-yl acetate (700 mg,
1.6 mmol) in THF/methanol 2:1, CeCl3$7H2O (745 mg,
2 mmol) was added and the mixture was stirred for 10 min
at room temperature before NaBH4 (120 mg, 3.2 mmol,
8 equiv) was slowly added. After 30 min, the reaction was
complete (TLC monitoring) and HCl 5% was added
dropwise. The mixture was poured into water and extracted
with diethyl ether. The organic solution was washed with
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evaporated to dryness, yielding 3b-hydroxycholestan-2a-yl
acetate (641 mg, 91%), as a white powder, mp 73–75 8C.
Selected data: 1H NMR (CDCl3) d: 0.64 (3H, s, CH3-18),
0.84–0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 2.08
(3H, s, CH3CO), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a),
4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b). 13C NMR d:
171.59, 76.49, 73.53, 56.28, 56.17, 54.17, 44.43, 42.52,
42.12, 39.81, 39.47, 37.27, 36.11, 35.89, 35.73, 34.70,
31.79, 28.19, 27.97, 27.77, 24.15, 23.77, 22.79, 22.53,
21.38, 18.63, 13.09, 12.02.
3b-Hydroxycholestan-2a-yl acetate (500 mg, 1.12 mmol)
was treated with NaOH as described in Section 4.2.1. The
crude product was purified by flash chromatography
(petroleum ether/ethyl acetate 4:1), rendering cholestane-
2a,3b-diol (2, 370 mg, 82%), which was crystallized from
methanol, mp 196.0–197.5 8C (lit.22b 204 8C).
Selected data: 1H NMR (CDCl3) d: 0.64 (3H, s, CH3-18),
0.84–0.91 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 3.40
(1H, ddd, JZ5.1, 8.9, 10.9 Hz, H-3a), 3.59 (1H, ddd, JZ
4.7, 9.0, 11.5 Hz, H-2b). 13C NMR d: 73.11, 72.3, 56.30,
56.20, 54.26, 45.03, 44.83, 39.89, 39.48, 38.14, 37.46,
36.13, 35.77, 35.57, 34.73, 31.88, 28.23, 28.00, 27.91,
24.17, 23.80, 22.81, 22.55, 21.36, 18.64, 13.50, 12.04. FTIR
(ATR): nmax 1051.0, 2850.1–2930.3, 3312.9 cm
K1.
4.2.3. Cholestane-2a,3a-diol (3). A solution of K3Fe(CN)6
(1 g), Et3N (7 ml), K2CO3 (420 mg) and methanesulphona-
mide (96 mg) in 20 ml of t-BuOH/H2O (3:2) was prepared.
Cholest-2-ene (370 mg, 1 mmol), (Section 4.2.1) was
dissolved in 30 ml THF/t-BuOH/H2O (10:3:2) and added
to the previous solution. Then, 30 ml of OsO4 solution
(0.1 mg/ml in CH3CN) was added and the reaction was
stirred at room temperature until the total consumption of
the starting material (48 h). Sodium sulphite 5% was added
and the mixture was stirred for 5 h. Upon addition of diethyl
ether, the organic layer was washed with HCl 5%, saturated
bicarbonate solution and brine, and then, evaporated. The
residue was purified by flash chromatography (petroleum
ether/ethyl acetate 4:1), rendering cholestane-2a,3a-diol
(3, 242 mg), which was crystallized from n-hexane, mp
217–218 8C (lit.22b 216–219 8C).
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.80 (3H, s, CH3-19), 0.86 (6H, two d, JZ6.6 Hz, CH3-26
and CH3-27), 0.90 (3H, d, JZ6.6 Hz, CH3-21), 3.77 (1H, br
d, JZ11.0 Hz, 2b-H), 3.96 (1H, br s, 3b-H). 13C NMR d:
69.27, 69.12, 56.35, 56.16, 54.16, 42.55, 40.93, 39.90,
39.49, 38.14, 36.90, 36.13, 35.78, 34.76, 34.22, 31.82,
28.22, 28.00, 27.65, 24.17, 23.80, 22.81, 22.55, 20.90,
18.65, 12.40, 12.06. FTIR (ATR): nmax 1048.7, 2852.2–
2930.0, 3315.0 cmK1.
4.2.4. Cholestane-2b,3a-diol (4). A mixture of cholest-2-
ene (400 mg, 1.1 mmol), CHCl3 (15 ml) and 3-chloro-
peroxybenzoic acid (400 mg, 2.3 mmol) was stirred at room
temperature. After the disappearance of the starting material
(24 h), the reaction mixture was poured into water and
extracted with CH2Cl2. The organic phase was washed with
sodium sulphite 5%, water and brine, dried with MgSO4 andevaporated at reduced pressure, affording 2a,3a-epoxy-
cholestane (395 mg, 93%).
Selected data: 1H NMR (CDCl3) d: 0.64 (3H, s, CH3-18),
0.75 (3H, s, CH3-19), 0.86 (6H, two d, JZ6.6 Hz, CH3-26
and CH3-27), 0.90 (3H, d, JZ6.5 Hz, CH3-21), 3.14 (2H, m,
H-2b and H-3b).
According to a known procedure,28 to a solution of 2a,3a-
epoxycholestane (374 mg, 0.9 mmol) in acetone (30 ml),
periodic acid (350 mg) in acetone/water (1:1.5 ml) was
added and the mixture was heated to reflux for 5 min, then
concentrated until 1/3 of the initial volume and kept at room
temperature for 30 min. This mixture was refluxed again
while water (2 ml) was added dropwise for 30 min. Finally,
the mixture was cooled, concentrated under vacuum and
purified by flash chromatography (petroleum ether/ethyl
acetate 4:1), yielding cholestane-2b,3a-diol (4, 309 mg,
85%), which was crystallized from methanol, mp 183–
185 8C (lit. 178–1801b and 197–20021a 8C).
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.86 (6H, two d, JZ6.6 Hz, CH3-26 and CH3-27), 0.90 (3H,
d, JZ6.5 Hz, CH3-21), 0.99 (3H, s, CH3-19), 3.87 (2H, m,
H-2a and H-3b). 13C NMR d: 71.82, 70.61, 56.41, 56.19,
55.10, 42.60, 40.54, 40.01, 39.49, 38.93, 36.14, 35.78,
35.73, 34.88, 31.90, 31.71, 28.20, 28.01, 24.13, 23.80,
22.82, 22.55, 20.86, 18.64, 14.59, 12.10. FTIR (ATR): nmax
1047.9, 2843.2–2930.9, 3310.1 cmK1.4.2.5. Androstane-3b,4b,17b-triol (5). A mixture of
testosterone acetate (661 mg, 2 mmol), glacial acetic acid
(30 ml) and zinc dust (4 g) was stirred at room temperature.
After disappearance of the starting material (5 h), diethyl
ether was added and the suspension was filtered through a
celite pad. The filtrate was evaporated under reduced
pressure, then dissolved in diethyl ether and washed with
water, saturated sodium bicarbonate solution and brine.
After drying with MgSO4, the organic phase was evapo-
rated, affording an epimeric mixture of 5a- and 5b-androst-
3-en-17b-yl acetate (595 mg, 94%).
Selected data: 1H NMR (CDCl3) d: 0.78 (3H, s, 18-CH3),
0.80 and 0.96 (3H, two s, 19-CH3), 2.03 (3H, s, CH3CO),
4.56 (1H, m, H-17a), 5.29 (1H, dq, H-4), 5.54 and 5.66 (1H,
two m, H-3). The 5a- and 5b- epimeric ratio, evaluated by
the integration of the H-3 multiplets,29 was 0.8:1. Epimeri-
cally pure 5a-androst-3-en-17b-yl acetate was obtained
after 3 sequential crystallizations in n-hexane.
5a-Androst-3-en-17b-yl acetate (200 mg, 0.63 mmol)
reacted with I2/Cu(OAc)2, the product obtained was treated
with NaOH (Section 4.2.1) and purified by flash chroma-
tography (petroleum ether/ethyl acetate 1:2), rendering
androstane-3b,4b,17b-triol (5, 95 mg), as a white amor-
phous powder, mp 257–260 8C (lit.30 263–265 8C).
Selected data: 1H NMR (CDCl3/CD3OD) d: 0.72 (3H, s,
CH3-18), 1.04 (3H, s, CH3-19), 3.50 (1H, m, H-3a), 3.57
(1H, t, JZ8.6 Hz, H-17a), 3.68 (1H, br t, JZ2.30 Hz,
H-4a). 13C NMR d: 81.89, 75.12, 72.67, 56.03, 51.64, 43.42,
37.66, 37.17, 36.12, 36.05, 32.54, 30.09, 26.34, 25.80,
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2845.5–2934.2, 3308.3 cmK1.4.2.6. Androstane-3b,4a,17b-triol (6). Testosterone
(288.4 mg, 1 mmol) was dissolved in THF (10 ml) and
cooled to 0 8C. Then, BH3 in THF (1.0 M, 5 ml) was added
slowly. The mixture was stirred for 3 h, then warmed to
room temperature over 2.5 h and cautiously quenched with a
10 N NaOH aqueous solution (2 ml), followed by slow
addition of a 30% H2O2 aqueous solution (2 ml). This
mixture was stirred overnight, then poured into water and
extracted with diethyl ether. The organic layers were
washed with HCl 5%, saturated bicarbonate solution and
brine. After drying with MgSO4, the solvent was evaporated
at reduced pressure and the residue purified by flash
chromatography (petroleum ether/ethyl acetate 1:2), render-
ing androstane-3b,4a,17b-triol (6, 246 mg, 80%), which
was crystallized from methanol, mp 253.3–255.8 8C (lit.
248–25023a and 258–25930 8C).
Selected data: 1H NMR (CDCl3/CD3OD) d: 0.72 (3H, s,
CH3-18), 0.85 (3H, s, CH3-19), 3.20 (1H, t, JZ8.7 Hz,
H-4b), 3.29 (1H, m, H-3a), 3.59 (1H, t, JZ8.5 Hz, H-17a).
13C NMR d: 81.87, 76.52, 75.53, 55.24, 51.53, 51.48, 43.38,
37.75, 37.23, 36.85, 35.68, 31.76, 30.13, 28.78, 23.77,
23.10, 21.10, 13.89, 11.47. FTIR (ATR): nmax 1066.0,
2847.5–2932.0, 3309.1 cmK1.4.2.7. Androstane-3a,4a,17b-triol (7). 5a-Androst-3-en-
17b-yl acetate (200 mg, 0.63 mmol) (Section 4.2.5) was
oxidized by OsO4 (Section 4.2.3). The product was treated
with NaOH (Section 4.2.1) and purified by flash chroma-
tography (petroleum ether/ethyl acetate 1:2), affording
androstane-3a,4a,17b-triol (7, 110.6 mg, 57%).
Selected data: 1H NMR (CDCl3/CD3OD) d: 0.72 (3H, s,
CH3-18), 0.85 (3H, s, CH3-19), 3.45 (1H, d, JZ10.2 Hz,
H-4b), 3.6 (1H, t, JZ8.5 Hz, H-17a), 3.97 (1H, s, H-3b).
13C NMR d: 82.40, 73.56, 70.14, 54.19, 50.76, 42.52, 37.50,
37.11, 36.89, 34.90, 31.76, 31.10, 23.47, 22.58, 21.20,
20.30, 12.70, 11.49. FTIR (ATR): nmax 1065.0, 2846.1–
2933.3, 3307.8 cmK1.4.2.8. Androstane-3a,4b,17b-triol (8). 5a-Androst-3-en-
17b-yl acetate (290 mg, 0.92 mmol) obtained as described
above (2.5) reacted with 3-chloroperoxybenzoic (Section
4.2.4). The product obtained was treated with periodic acid
(Section 4.2.4), deacetylated with NaOH (Section 4.2.1)
and purified by flash chromatography (petroleum ether/
ethyl acetate 1:2), affording androstane-3a,4b,17b-triol
(8, 142 mg), which was crystallized from methanol, mp
263–264.3 8C.
Selected data: 1H NMR (CDCl3/CD3OD) d: 0.71 (3H, s,
CH3-18), 1.03 (3H, s, CH3-19), 3.49 (1H, br s, H-4a), 3.55
(1H, t, JZ8.6 Hz, H-17a), 3.75 (1H, br q, JZ2.6 Hz, H-3b).
13C NMR d: 82.54, 76.56, 71.24, 56.94, 52.51, 45.24, 44.08,
37.99, 37.09, 36.96, 33.32, 33.21, 30.61, 26.60, 25.11,
24.31, 20.97, 14.85, 11.67. FTIR (ATR): nmax 1064.9,
2849.8–2935.1, 3309.5 cmK1. FD-MS m/zZ308.2386
(100%, MC), 309.2424 (27%, MCC1), 290.2237 (17%,
MCKH2O).4.2.9. Cholestane-3b,4a-diol (9). Hydroboration of
cholest-4-en-3-one (384 mg, 1 mmol) under the conditions
described in Section 4.2.8 rendered cholestane-3b,4a-diol
(9, 352 mg, 87%), which was crystallized from n-hexane,
mp 235–237 8C (lit.31 237 8C).
Selected data: 1H NMR (CDCl3) d: 0.62 (3H, s, CH3-18),
0.79–0.87 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 3.18
(1H, t, JZ10.2 Hz, H-4b), 3.29 (1H, m, H-3a). 13C NMR d:
76.24, 75.25, 56.54, 56.37, 54.6, 50.86, 42.63, 40.08, 39.62,
37.28, 36.36, 36.27, 35.92, 35.16, 31.74, 28.37, 28.26,
28.11, 24.28, 23.93, 22.83, 22.78, 22.58, 21.08, 18.70,
13.58, 12.11. FTIR (ATR): nmax 1047.1, 2851.2–2930.2,
3315.0 cmK1.4.3. Enzymatic acylation of 2,3- and 3,4-vicinal diols
In a typical screening assay, a solution of the substrate
(2 mg), in 0.9 ml of solvent (toluene for the cholestane diols
or acetone/THF for the androstane diols) and vinyl acetate
(0.1 ml) was prepared. This solution was added to the
enzyme (30 mg of crude enzymes, 10 mg of Lipozyme IM
20 or 5 mg of Novozym 435) in 3 ml vials, which were
stopped with a cap and shaken at 250 rpm at 45 8C. The
reactions were monitored by TLC (see Table 1).4.3.1. 2b-Hydroxycholestan-3b-yl acetate (1a). To a
solution of cholestane-2b, 3b-diol (1, 25 mg, 0.062 mmol)
in toluene (8 ml) and vinyl acetate (2 ml), Candida rugosa
lipase (100 mg) was added and the reaction was shaken at
250 rpm, at 45 8C. After 24 h the reaction was complete.
The enzyme was filtered off and the solvent was evaporated,
the residue was purified by flash chromatography (petro-
leum ether/ethyl acetate 5:1) yielding 2b-hydroxycholestan-
3b-yl acetate (1a, 22 mg, 80%), which was crystallized from
methanol, mp 147–148 8C (lit.26 154 8C).
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.86 (6H, two d, JZ6.5 Hz, CH3-26 and CH3-27), 0.89 (3H,
d, JZ6.5 Hz, CH3-21), 1.03 (3H, s, CH3-19), 2.08 (3H, s,
CH3CO), 4.09 (1H, br q, JZ2.6 Hz, H-2a), 4.78 (1H, ddd,
JZ3.34, 4.71, 11.75 Hz, H-3a). 13C NMR d: 170.13, 75.58,
68.72, 56.30, 56.19, 55.15, 45.40, 42.90, 42.59, 39.95,
39.47, 36.12, 35.76, 35.30, 34.77, 31.86, 28.58, 28.20,
28.13, 27.98, 24.13, 23.79, 22.80, 22.54, 21.34, 21.22,
18.62, 14.51, 12.07. FTIR (ATR): nmax 1025.1, 1259.3,
1721.8, 2858.0–2950.2, 3510.8 cmK1. FD-MS m/zZ
386.3462 (100%, MCKCH3COOH), 447.3828 (83%,
MCC1), 404.3776 (67%, MCC1KCH3CO), 448.3870
(25%, MCC2), 61.0324 (8%, CH3COOHC1).4.3.2. 2a-Hydroxycholestane-3b-yl acetate (2a). To a
solution of cholestane-2a, 3b-diol (2, 50 mg, 0.124 mmol)
in toluene (8 ml), vinyl acetate (1 ml) and lipase PS
(100 mg) were added and the reaction mixture was shaken
for 24 h, under the conditions described above. After usual
work-up and purification by flash chromatography, 2a-
hydroxycholestane-3b-yl acetate was recovered (2a, 48 mg,
87%) as a white powder, mp 157–159 8C. The TLC Rf of 2a
and of 3b-hydroxycholestan-2a-yl acetate (synthesised in
Section 4.2.2) using petroleum ether/ethyl acetate (2:1) as
eluent were 0.47, and 0.39, respectively.
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0.84–0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 2.08
(3H, s, CH3CO), 3.77 (1H, ddd, JZ4.8, 9.4, 11.5 Hz, H-2b),
4.59 (1H, ddd, JZ5.4, 9.5, 10.9 Hz, H-3a). 13C NMR d:
171.37, 78.99, 69.85, 56.13, 56.09, 54.03, 45.28, 44.34,
42.46, 39.75, 39.39, 36.81, 36.03, 35.68, 34.62, 32.53,
31.69, 30.82, 28.13, 27.90, 27.63, 24.08, 23.70, 22.70,
22.44, 21.25, 18.54, 13.17, 11.94. FTIR (ATR): nmax 1025.9,
1259.8, 1718.8, 2857.0–2951.3, 3512.1 cmK1. FI-MS m/zZ
386.3553 (100%, MCKCH3COOH), 446.3842 (54%, M
C),
387.3591 (35%, MCC1KCH3COOH), 447.3853 (33%,
MCC1), 61.0251 (1%, CH3COOHC1).
4.3.3. 2a-Hydroxycholestane-3a-yl acetate (3a). To a
solution of cholestane-2a,3a-diol (3, 40 mg, 0.1 mmol) in
toluene (8 ml), vinyl acetate (1 ml) and Novozym 435
(80 mg) were added and the reaction mixture was shaken
for 2 days, under the conditions described above. After
usual work-up and purification by flash chromatography,
2a-hydroxycholestane-3a-yl acetate was recovered (3a,
33 mg, 75%) and crystallized from methanol, mp 163–164 8C.
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.82 (3H, s, CH3-19), 0.87 (6H, two d, JZ6.5 Hz, CH3-26
and CH3-27), 0.90 (3H, d, JZ6.5 Hz, CH3-21), 2.12 (3H, s,
CH3CO) 3.84 (1H, dt, JZ4.2, 11.4 Hz, H-2b), 5.12 (1H, br
q, JZ2.6 Hz, H-3b). 13C NMR d: 171.58, 73.03, 68.11,
56.33, 56.23, 54.14, 42.57, 41.70, 39.88, 39.47, 39.29,
36.74, 36.13, 35.78, 34.71, 32.21, 31.77, 28.23, 27.99,
27.45, 24.16, 23.83, 22.81, 22.54, 21.38, 20.89, 18.63,
12.55, 12.04. FTIR (ATR): nmax 1027.4, 1259.8, 1714.7,
2859.0 2952.5, 3516.3 cmK1. FI-MS m/zZ446.3828
(100%, MC), 386.3293 (91%, MCKCH3COOH),
447.3842 (29%, MCC1), 387.3349 (23%, MCC1K
CH3COOH).
4.3.4. 2b-Hydroxycholestane-3a-yl acetate (4a). To a
solution of cholestane-2b,3a-diol (4, 50 mg, 0.124 mmol) in
toluene (10 ml), vinyl acetate (1 ml) and Novozym 435
(80 mg) were added and the reaction mixture was shaken
for 3 days, under the conditions described above. After
usual work-up and purification by flash chromatography,
2b-hydroxycholestane-3a-yl acetate was recovered as a
single product (4a, 47.6 mg, 86%), mp 110–111 8C (lit.1b
106–107 8C).
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.86 (6H, two d, JZ6.6 Hz, CH3-26 and CH3-27), 0.90 (3H,
d, JZ6.5 Hz, CH3-21), 0.99 (3H, s, CH3-19), 2.07 (3H, s,
CH3CO), 3.88 (1H, br s, H-2a), 4.82 (1H, br s, H-3b).
13C
NMR d: 170.52, 72.92, 68.65, 56.43, 56.25, 54.97, 42.58,
40.46, 39.99, 39.89, 39.46, 36.13, 35.77, 35.34, 34.81,
31.85, 28.66, 28.21, 27.97, 24.11, 23.83, 22.80, 22.53,
21.40, 20.81, 18.62, 14.18, 12.06. FTIR (ATR): nmax 1033.1,
1261.2, 1714.2, 2860.1–2953.8, 3500.3 cmK1.
4.3.5. 3a-Hydroxycholestane-2b-yl acetate (4b). To a
solution of cholestane-2b,3a-diol (4, 50 mg, 0.124 mmol) in
toluene (9 ml), vinyl acetate (1 ml) and lipase PS (200 mg)
were added and the reaction mixture was shaken for 3 days,
under the conditions described above. After usual work-up
and purification by flash chromatography, 3a-hydroxy-
cholestane-2b-yl acetate was recovered as a single product(4b, 37 mg, 67%), mp 115.7–116.2 8C (lit. 85–861b and
11327 8C).
Selected data: 1H NMR (CDCl3) d: 0.64 (3H, s, CH3-18),
0.86 (6H, two d, JZ6.6 Hz, CH3-26 and CH3-27), 0.89 (3H,
d, JZ5.3 Hz, CH3-21), 0.90 (3H, s , CH3-19), 2.04 (3H, s,
CH3CO), 3.84 (1H, br q, JZ2.3 Hz, H-3b), 4.87 (1H, br q,
H-2a). 13C NMR d: 170.30, 73.15, 67.59, 56.35, 56.17,
54.85, 42.55, 39.92, 39.48, 38.52, 37.10, 36.12, 35.77, 35.56
34.94, 31.84, 31.74, 28.19, 28.11, 27.99, 24.12, 23.81,
22.80, 22.54, 21.44, 20.20, 18.63, 13.64, 12.06. FTIR
(ATR): nmax 1034.5, 1263.2, 1716.4, 2862.8–2928.4,
3481.8 cmK1.
4.3.6. 4b,17b-Dihydroxyandrostane-3b-yl acetate (5a).
To a solution of androstane-3b,4b,17b-triol (5, 35 mg,
0.114 mmol) in toluene (5 ml), THF (5 ml) and vinyl acetate
(1 ml), Candida rugosa lipase (100 mg) was added and the
reaction mixture was shaken for 3 days, under the conditions
described above. After usual work-up and purification by
flash chromatography (petroleum ether/ethyl acetate 2:1),
4b,17b-dihydroxyandrostan-3b-yl acetate was recovered
(5a, 29.3 mg, 74%).
Selected data: 1H NMR (CDCl3) d: 0.73 (3H, s, CH3-18),
1.06 (3H, s, CH3-19), 2.09 (3H, s, CH3CO), 3.63 (1H, t, JZ
8.7 Hz, H-17a), 3.83 (1H, br t, H-4a), 4.72 (1H, ddd, JZ
3.2, 4.8, 8.0 Hz, H-3a). 13C NMR d: 170.27, 81.87, 75.53,
72.88, 55.29, 50.98, 48.71, 42.93, 36.85, 36.54, 35.61,
35.44, 31.82, 30.45, 25.55, 23.34, 22.13, 21.34, 20.11,
14.71, 11.11. FTIR (ATR): nmax 1041.5, 1258.2,
1709.3, 2840.9–2943.0, 3442.0 and 3530.1 cmK1. FD-MS
m/zZ351.2470 (100%, MCC1), 290.2104 (78%, MCK
CH3COOH), 350.2468 (37%, M
C).
4.3.7. 4a,17b-Dihydroxyandrostane-3b-yl acetate (6a).
To a solution of androstane-3b,4a,17b-triol (6, 30 mg,
0.1 mmol) in acetone (6 ml), THF (3 ml) and vinyl acetate
(1 ml), Chromobacterium viscosum lipase (200 mg) was
added and the reaction mixture was shaken for 3 days, under
the conditions described above. After usual work-up and
purification by flash chromatography, 4a,17b-dihydroxy-
androstan-3b-yl acetate was recovered (6a, 20.2 mg, 60%),
and crystallized from methanol, mp 182–184 8C.
Selected data: 1H NMR (CDCl3) d: 0.73 (3H, s, CH3-18),
0.86 (3H, s, CH3-19), 2.09 (3H, s, CH3CO), 3.46 (1H, t, JZ
9.5 Hz, H-4b), 3.64 (1H, t, JZ8.5 Hz, H-17a), 4.58 (1H,
ddd, JZ5.4, 9.2, 11.6 Hz, H-3a). 13C NMR d: 171.51,
81.85, 79.23, 72.48, 54.32, 51.29, 50.83, 42.88, 36.58,
36.01, 35.05, 31.00, 30.50, 25.62, 23.32, 22.48, 21.37,
20.54, 15.26, 13.51, 11.11. FTIR (ATR): nmax 1035.6,
1262.2, 1707.7, 2841.6–2940.9, 3443.3 and 3522.3 cmK1.
FI-MS m/zZ290.2061 (100%, MCKCH3COOH),
350.2541 (39%, MC), 291.2042 (12%, MCC1K
CH3COOH).
4.3.8. 3a,17b-Dihydroxyandrostan-4a-yl acetate (7a).
To a solution of 3a,4a,17b-trihydroxyandrostane (7,
118 mg, 0.38 mmol) in acetone (18 ml), THF (4 ml) and
vinyl acetate (2 ml), lipase PS (500 mg) was added and the
reaction mixture was shaken for 4 days, under the conditions
described above. After usual work-up and purification by
M. M. Cruz Silva et al. / Tetrahedron 61 (2005) 3065–30733072flash chromatography, 3a,17b-dihydroxyandrostan-4a-yl
acetate was recovered (7a, 102.3 mg, 76%) as a white
powder.
Selected data: 1H NMR (CDCl3) d: 0.72 (3H, s, CH3-18),
0.87 (3H, s, CH3-19), 2.09 (3H, s, CH3CO), 3.64 (1H, t, JZ
8.5 Hz, H-17a), 4.01 (1H, q, JZ2.9, 2.7 Hz, H-3b). 4.85
(1H, dd, JZ11.8, 2.9 Hz, H-4b). 13C NMR d: 171.24, 82.76,
75.20, 67.58, 54.11, 50.67, 42.83, 42.48, 37.68, 36.80,
34.79, 31.14, 30.84, 27.48, 26.75, 23.41, 22.42, 21.13,
20.27, 12.82, 11.51. FTIR (ATR): nmax 1039.2, 1265.1,
1710.7, 2841.6, 3445.7 and 3528.1 cmK1. FI-MS m/zZ
308.2328 (100%, MCC1KCH3CO), 290.2052 (71%,
MCKCH3COOH), 350.2441 (62%, M
C), 332.2306 (26%,
MCKH2O), 351.2468 (12%, M
CC1).
4.3.9. 4a-Hydroxycholestane-3b-yl acetate (9a). To a
solution of cholestane-3b,4a-diol (9, 50 mg, 0.124 mmol) in
acetone (9 ml), vinyl acetate (1 ml) and Chromobacterium
viscosum lipase (500 mg) were added and the reaction
mixture was shaken under the conditions described above
for 6 days. The usual work-up and flash chromatography
yielded 4a-hydroxycholestane-3b-yl acetate (9a, 42.3 mg,
76%), mp 169–170 8C.
Selected data: 1H NMR (CDCl3) d: 0.65 (3H, s, CH3-18),
0.84–0.91 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 2.08
(3H, s, CH3CO), 3.45 (1H, t, JZ9.7 Hz, H-4b), 4.57 (1H,
ddd, JZ5.3, 9.1, 11.5 Hz, H-3a). 13C NMR d: 171.49,
79.24, 72.47, 56.30, 56.18, 54.21, 51.23, 42.45, 39.85,
39.46, 36.83, 36.10, 35.96, 35.76, 34.97, 31.44, 28.22,
27.97, 25.65, 24.12, 23.80, 22.79, 22.60, 21.53, 21.36,
20.94, 18.61, 13.46, 12.01. FTIR (ATR): nmax 1036.6,
1263.2, 1715.4, 2860.9–2930.2, 3549.3 cmK1. FI-MS m/zZ
386.3400 (100%, MCKCH3COOH), 446.3787 (33%, M
C),
387.3417 (27%, MCC1KCH3COOH), 447.3893 (13%,
MCC1).Acknowledgements
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